Skip to main content

Remifentanil Injection Shortage

Last Updated: November 27, 2023
Status: Current

Products Affected - Description
    • Remifentanil lyophilized powder for injection, Fresenius Kabi, 5 mg, vial, 10 count, NDC 63323-0725-10
    • Remifentanil lyophilized powder for injection, Hikma, 1 mg, vial, 10 count, NDC 00143-9391-10
Reason for the Shortage
    • Fresenius Kabi did not provide a reason for the shortage.
    • Hikma did not provide a reason for the shortage.
    • Viatris did not provide a reason for the shortage.
Available Products
    • Ultiva lyophilized powder for injection, Mylan Institutional (Viatris), 1 mg, vial, 10 count, NDC 72078-0034-01
    • Ultiva lyophilized powder for injection, Mylan Institutional (Viatris), 2 mg, vial, 10 count, NDC 72078-0035-02
    • Ultiva lyophilized powder for injection, Mylan Institutional (Viatris), 5 mg, vial, 10 count, NDC 67457-0198-10
    • Remifentanil lyophilized powder for injection, Fresenius Kabi, 1 mg, vial, 10 count, NDC 63323-0723-03
    • Remifentanil lyophilized powder for injection, Fresenius Kabi, 2 mg, vial, 10 count, NDC 63323-0724-05
    • Remifentanil lyophilized powder for injection, Hikma, 2 mg, vial, 10 count, NDC 00143-9392-10
    • Remifentanil lyophilized powder for injection, Hikma, 5 mg, vial, 10 count, NDC 00143-9393-10

Estimated Resupply Dates

    • Fresenius Kabi has remifentanil 5 mg vials on back order and the company estimates a release date of late-November to early-December 2023.
    • Hikma has remifentanil 1 mg vials on back order and the company cannot estimate a release date.

Updated

Updated November 27, 2023 by Michelle Wheeler, PharmD, Drug Information Specialist. Created June 22, 2022 by Leslie Jensen, PharmD, Drug Information Specialist. © 2023, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer